U.S. regulators are considering whether two anemia-fighting drugs, often given to cancer patients, may in some cases stimulate tumor growth, a question raised by studies of similar products sold in Europe. The Food and Drug Administration has scheduled a meeting of outside experts for May 4 to gather input on safety issues surrounding the medicines, Amgen Inc.'s Aranesp and Johnson & Johnson’s Procrit.
